Telisotuzumab Vedotin Yields Durable Responses in c-Met-Expressing NSCLC

Telisotuzumab vedotin shows promising activity in previously treated, c-Met-overexpressing, EGFR-wild-type nonsquamous non-small cell lung cancer (NSCLC), as presented by CU Cancer Center member David Ross Camidge, MD, PhD, at the ASCO Annual Meeting 2024. This phase 2 LUMINOSITY trial (NCT03539536) involved 161 patients with advanced or metastatic NSCLC and the overall response rate was 28.6%, with median progression-free survival of 5.7 months and median overall survival of 14.5 months.